COPENHAGEN, DENMARK (PRWEB) NOVEMBER 12, 2020 Today, Octarine Bio ApS (“Octarine” or the “Company”), a synthetic biology company developing biosynthetic platforms for cannabinoids, psychedelics and their novel improved...
Funding & investments
Hyasynth completes key commercialization milestone for cannabinoid biosynthesis, receives $2.5 million payment
Hyasynth receives $2.5 million milestone payment following first-to-market achievement with CBD produced by fermentation MONTREAL, Oct. 23, 2020 /CNW Telbec/ – Hyasynth, a sustainable biotechnology company, has...
